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Abstract
In 2012, the Centers for Disease Control and Prevention (CDC) adopted its Advisory Committee 
on Childhood Lead Poisoning Prevention (ACCLPP) recommendation to use a population-based 
reference value to identify children and environments associated with lead hazards. The current 
reference value of 5 μg/dL is calculated as the 97.5th percentile of the distribution of blood lead 
levels (BLL) in children one to five years old from 2007–2010 National Health and Nutrition 
Examination Survey (NHANES) data. We calculated and updated selected percentiles, including 
the 97.5th percentile, using NHANES 2011–2014 blood lead data and examined demographic 
characteristics of children whose blood lead was ≥90th percentile value. The 97.5% percentile BLL 
of 3.48 μg/dL highlighted analytical laboratory and clinical interpretation challenges of blood lead 
measurements ≤ 5 μg/dL. Review of five years of results for target blood lead values < 11 μg/dL 
for U.S. clinical laboratories participating in CDC’s voluntary Lead and Multi-Element 
Proficiency (LAMP) quality assurance program showed 40% unable to quantify and reported a 
non-detectable result at a target blood lead value of 1.48 μg/dL compared 5.5 % at a target blood 
lead of 4.60 μg/dL. We describe actions taken at CDC’s Environmental Health Laboratory in the 
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Division of Laboratory Sciences, which measures blood lead for NHANES, to improve analytical 
accuracy and precision and to reduce external lead contamination during blood collection and 
analysis.
Introduction
No safe blood lead concentration in children has been identified.1,2 Lead can affect nearly 
every system in the body and is especially harmful to the developing central nervous systems 
of children.3. Chronic lead exposure may occur with no obvious symptoms, but it has been 
associated with developmental delay, sluggishness and fatigue, weight loss, irritability and 
difficulties learning.3 In 2012, the Centers for Disease Control and Prevention’s Advisory 
Committee on Childhood Lead Poisoning Prevention (ACCLPP) recommended using a 
population-based reference value, calculated as the 97.5th percentile of blood lead in 
children one to five years old in the U.S., instead of a blood lead “level of concern” to 
identify children and environments associated with lead hazards.2 Based upon the 2007–
2010 National Health and Nutrition Examination Survey (NHANES) blood lead results, the 
reference value was 5 μg/dL. The ACCLPP recommended that CDC update the reference 
value every four years using the most recent NHANES blood lead data for children ages one 
to five years old.2 CDC concurred or concurred in principle with the ACCLPP 
recommendations.4
Using available NHANES 2011–2014 data, we calculated the 97.5th percentile at 3.48 μg/dL 
(95% confidence interval, 2.65, 4.29 μg/dL), approximately 30% lower than the current 
reference value. Our objective is to describe the laboratory implications of a decreasing 
trend in blood lead concentrations (referred to as blood lead levels, BLLs) in U.S. children 
and the clinical interpretation challenges that result from the variability of measurement of 
low BLLs. Because the CDC has not made a final decision about changing the current 
reference value of 5 μg/dL we refer to a calculated 97.5th percentile rather than a reference 
value.
The Challenge for Laboratories that Measure Blood Lead
As BLLs in U.S. children have declined over time (see Figure), acceptability criteria for 
laboratory performance of blood lead analysis in proficiency testing (PT) programs have 
become more rigorous, requiring laboratories to change processes and technologies. Prior to 
1992, PT performance was judged satisfactory if the laboratory reported results for test 
samples that were within ± 6 μg/dL or ± 15% of the assigned (target) concentration for 
individual PT samples.5 The Clinical Laboratory Improvement Amendments (CLIA) of 
1988 tightened the acceptability criteria for blood lead measurements to ± 4 μg/dL or ± 10%, 
whichever is greater.6 In 2010, the ACCLPP recommended that the criteria be reduced to ± 2 
μg/dL or ± 10%, whichever is greater,2 noting that the majority of laboratories measuring 
blood lead were already achieving measurement errors of ± 2 μg/dL at these concentrations.7 
However, the acceptability criteria in the CLIA regulations have not been updated.
Measuring ever-lower BLLs required laboratories to shift to newer technologies with lower 
method limits of detection (LODs) and improved accuracy and precision. Methodology in 
Caldwell et al. Page 2
Pediatrics. Author manuscript; available in PMC 2017 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
the 1970’s was based on flame absorption spectroscopy, later followed by methods based on 
electrothermal atomic absorption spectrometry, and anodic stripping voltammetry. In the 
1990s inductively coupled plasma mass spectrometry (ICP-MS) was introduced and newer 
generations of ICP-MS have even higher sensitivity and lower background levels. These 
changes in analytical methodology have made it possible for laboratories to achieve lower 
LODs and make accurate, precise blood lead measurements significantly below 5 μg/dL. 
Nonetheless, achieving accurate and precise measurements at blood lead concentrations < 5 
μg/dL is an analytical challenge using CLIA-exempt instruments (e.g., LeadCare® II 
analyzer with an LOD of 3.3 μg/dL). In addition to using highly technical measurement 
methods, such as ICP-MS, special precautions are needed to avoid external lead 
contamination of the blood collection devices and instrument reagents.
The CDC’s Environmental Health Laboratory in the Division of Laboratory Sciences (EHL-
DLS) plays an important public health role in blood lead measurement that includes 
NHANES sample analysis that serve as reference values for U.S. children and adults. Lot 
screening has been an important activity used by CDC’s laboratory to exclude entire lots of 
items used in blood collection (e.g., butterfly needles, collection tubes, alcohol and iodine 
wipes) or analytical laboratory materials (e.g., pipette tips, reagents) with unacceptable lead 
contamination that could result in falsely elevated BLLs. In addition, the CDC’s ICP-MS 
analytical method timing, calibrator placement, calibration regression type, sample 
introduction system, and reagent composition were optimized for accurate and precise 
determination of lead in blood at low concentrations. By employing all these measures, the 
EHL-DLS achieved a blood lead LOD of 0.07 μg/dL for the 2013–2014 NHANES survey 
period.
As BLLs in U.S. children continue to decrease, more laboratories will need to be able to 
accurately measure concentrations below their current LODs. To accomplish this, 
laboratories will need to consider various modifications, including selecting the optimal 
analytical method as well as testing for lead contamination of laboratory reagents and 
supplies used in the laboratory (e.g., aliquotting devices, cryovials). Lead contamination also 
may occur during blood sample collection because of external skin contamination and small 
amounts of lead in the blood collections materials (e.g., needles, vials, anticoagulants in 
tubes). Precautions to avoid skin contamination during blood collection are well known to 
clinicians and clinics that conduct lead testing. However, manufacturers of blood collection 
devices may need to consider screening devices for even lower levels of lead contamination 
that interfere with laboratory measurements and take actions to prevent lead contamination 
during production.
Although each device, reagent, or item that has contact with a child’s blood may have only a 
small amount of lead, these sources are additive to a blood sample throughout the pre-
analytical and analytical process. Such contamination may have little impact to 
measurements of blood lead at values of 10 μg/dL or more; however, the sum of 
contamination sources may contribute significantly to blood lead measurements near or 
below the current reference value. It is a principle for blood lead or any analytical 
measurement that as the measurement approaches the LOD, the variability around the 
measurement increases significantly.8 Therefore, as BLLs continue to decline, laboratories 
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may need to lower their analytical LODs using analytical process improvements, technology 
changes, or both. We describe several approaches used by the EHL-DLS to improve 
analytical accuracy, precision, and to reduce lead contamination during blood collection and 
specimen analysis.
Methods
Data
CDC’s National Center for Health Statistics (NCHS) conducts the NHANES. The design is 
a complex, multistage, probability cluster sample designed to represent the U.S. population 
based on age, sex, and race/ethnicity.9 The survey has been continuous since 1999 and is 
intended to assess the health and nutritional status of the civilian, non-institutionalized U.S. 
population. Data is collected annually from about 5000 participants annually through 
interviews, surveys, physical examinations, and clinical specimens. Data are publicly 
released in 2-year cycles. The NHANES survey incorporates sample population weights to 
account for the unequal selection probabilities caused by the cluster design, non-response, 
and planned over-sampling of certain subgroups.9 The NCHS Ethics Review Board 
approved all content, and all participants provided signed, informed consent prior to data and 
specimen collection. Data from NHANES 2011–2014 used for this analysis were from 
public release files available from the NHANES website. We used blood lead values (in 
μg/dL) and the following sociodemographic variables: sex; age; race/ethnicity and annual 
household income. Age categories were 1–2, 3–4, and 5 years; race/ethnicity categories 
were self-reported as non-Hispanic white, non-Hispanic black, non-Hispanic Asian, and 
Hispanic, which includes Mexican American and other Hispanic. Annual household income 
was categorized as < $20,000, $20,000–44,999, and ≥ $45,000.
Lot screening
The EHL-DLS screens a representative sample (usually 50 items) from each manufacturing 
lot of devices that comes into contact with patient blood during collection, analysis, storage 
or are used in the laboratory’s analytical process for lead measurement. This screening is an 
essential preliminary step to accurately quantify blood lead as well as other metals. Without 
screening lots of collection and analytical materials and rejecting materials that are 
contaminated, there is a risk that one or more of the items could contain an amount of lead 
that is higher than LOD for the blood lead method. This can result in falsely elevated BLLs. 
Examples of materials screened include needles, blood tubes (evacuated blood tubes, 
capillary tubes, cryovial storage tubes), syringes, and lancets. Each device is set up in a 
manner that mimics the way it is used in the field.
Deionized water is used as the screening solution for blood collection and storage devices 
that are either composed of stainless steel (needles) or come into contact with the stainless 
steel containing devices (blood collection tubes). In general, the procedure involves rinsing a 
pre-determined volume of water through the device, such as a butterfly or a needle. The lead 
concentration is measured in each collected rinse solution. The procedure is similar for 
screening laboratory devices used in the analytical process, such as pipette tips and 
autosampler vials.
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A sample of analytical reagents from the same lot are also screened by measuring the lead 
concentration in a pre-determined aliquot. Screen failure is defined by an equation that is 
based on the sample volume used, the LOD (e.g., 0.25 μg/dL for blood lead in 2011–2012) 
and the expected mean concentration in the population (<1 μg/dL for 1–5 year old 
children).10 The equation is provided in the Supplemental Information. For each of its 
projects involving blood lead measurement, the laboratory either provides materials that 
have been screened or informs its collaborators of the manufacturer lot number that passed 
screening so that “clean” materials can be purchased.
Blood Lead Measurements
Whole blood specimens were collected by venipuncture using needles, disposable skin 
wipes, and blood collection tubes with anticoagulant. All collection supplies were lot 
screened and determined to be free of significant lead contamination. Samples were 
aliquoted with screened pipettes, and stored at ≤ −20° C until they were shipped on dry ice 
to the CDC’s EHL-DLS, where they were stored frozen (≤ −20° C) and analyzed within 
three weeks of collection.
Measurements were made11 using the ELAN® DRC II ICP-MS (PerkinElmer, Waltham, 
MA) and analysis tubes which had been previously lot screened. The method LOD was 0.25 
μg/dL for NHANES 2011–2012 and 0.07 μg/dL for NHANES 2013–2014. The CDC ICP-
MS analytical method timing, calibrator placement, calibration regression type, sample 
introduction system, and reagent composition were optimized for accurate and precise 
determination of lead at low concentrations in blood.
Lead and Multi-Element Proficiency (LAMP)
LAMP is a voluntary performance and quality assurance program designed to promote high 
quality whole blood lead, cadmium, mercury, selenium and manganese measurements.12 
Participating laboratories analyze a set of blood samples that CDC prepares using standard 
reference materials with analytical target values linked to the National Institute of Standards 
and Technologies Standard Reference Materials. The LAMP program ships three to four 
samples per challenge, four challenges a year, to the participating laboratories. After 
analyzing the samples in duplicate on two separate runs, each laboratory reports their results 
to CDC. CDC compiles the results by analytical method and reports both the laboratory 
group summary statistics as well as individual laboratory summary results compared to the 
CDC target value and the laboratory group or consensus means. The blood lead target values 
ranged from 0.18 to 66 μg/dL for the study period of 2011–2015. To evaluate the accuracy 
and precision of the participating laboratories for this report, we reviewed results with a 
target value <11 μg/dL and included only laboratories that were continuously participating 
since 2011. Approximately 180 laboratories are enrolled in LAMP, and 66 U.S. laboratories 
(15% academic, 6% federal government, 30% state government, 49% private) have been 
continuously participating since 2011, missing no more than three rounds during this period. 
We used an imputed value (LOD/√2) when results were submitted as <LOD. In this report, 
we evaluated performance in measuring blood lead at concentrations ≤11 μg/dL for the 
continuously participating laboratories.
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Statistical analysis
Percentiles
Percentiles for blood lead in children ages 1–5 years were calculated using SUDAAN 
version 11.0.0 (Research Triangle Institute, Research Triangle Park, NC, USA). SUDAAN 
uses sample weights and calculates variance estimates that account for the complex survey 
design. Confidence intervals for percentiles were adapted from the methods of Korn and 
Graubard13 and Woodruff.14
Children with BLLs at the 90th Percentile or Higher
Multiple logistic regression analysis was used to examine characteristics of children with 
BLLs at or above the 90th percentile, chosen to provide a larger sample size relative to the 
higher percentiles. Analyses were adjusted for sex, age group, race/ethnicity, and annual 
household income. An alpha (α) level of 0.05 was used to determine statistical significance.
Results
Lot Screening Failures
Because CDC’s analytical LOD for lead in whole blood has decreased over time, and BLLs 
in the U.S. population have decreased over time, lot screening has resulted in more 
“failures” due to unacceptable lead contamination. Between January 2009 and February 
2016, the laboratory screened 359 manufacturing lots of needles, blood collection tubes, 
cryovials, and other items for lead. The decline in LOD and BLLs in children one to five 
years old was accompanied by an increase in the percentage of lot screen failures. In 
NHANES 2009–2010, with a mean blood lead of 1.17 μg/dL and LOD of 0.3 μg/dL, less 
than 1% of 112 screened lots failed. In 2015, with a blood lead LOD of 0.07 μg/dL, the 
failure rate was 35% of 85 lots screened (Table 1).
Selected percentiles and 95% confidence intervals of blood lead concentration in children 
ages one to five years old from the NHANES survey periods 2011–2014 are presented in 
Table 2., as well as the 50th, 75th, 90th and 97.5th percentiles based on NHANES 2011–2014.
Children with BLLs at the 90th percentile or Higher
Children with BLLs at or above 3.48 μg/dL (97.5th percentile) were more likely to be 
younger than 3 years, male, of non-Hispanic black race/ethnicity, and reside in low income 
households (Table 3). However, annual household income less than $20,000 was the only 
significant predictor for a BLL at or above 3.48 μg/dL (p=0.0056).
Multiple logistic regression results are presented in Table 4. Both age and income were 
statistically significant. Relative to five year olds, children one to two years and three to four 
years had a 3.9 and 2.4 times higher risk, respectively, of having a BLL at the 90th percentile 
or higher. Children in households with annual incomes of <$20,000 and $20,000 - $44,999 
had a 9.0 and 4.9 times greater risk, respectively, for having a BLL at the 90th percentile or 
higher, relative to children from higher income households (≥$45,000 per year).
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LAMP
The LAMP challenge results for BLLs < 11 μg/dL are summarized in Table 5a. We found 
that overall, the participating laboratories had acceptable performance at all concentration 
challenges. More laboratories were accurate at determining BLLs > 5 μg/dL than at lower 
concentrations. On average 40% of the values reported by laboratories for samples with low 
BLLs (≤ 1.48 μg/dL) were reported as below the limit of detection (LOD). At 1.48 μg/dL or 
lower, no more than 60 % of laboratories reported actual values, and the average mean 
values (consensus mean) reported by the laboratories over-estimated the BLLs when the 
target value was <1 μg/dL. This over-estimation is due to imputation of results reported as 
<LOD, which uses a value of LOD/√2. Using sample ID 1503 (Table 5a) as an example, if a 
result was reported as <LOD, and the LOD was 3, the adjusted result was 2.1 μg/dL, 
whereas the target value was 0.18 μg/dL. The relative standard deviations (RSDs), an 
indicator of measurement precision, are also shown for each challenge sample in Table 5a. 
The precision of a measurement is directly related to concentration, so a measurement is 
more precise at a higher lead concentration than at a lower concentration. Consequently, 
RSDs for the challenge samples increased as the target values decreased. At the lowest BLL 
challenge sample (0.18 μg/dL), more than half of the laboratories reported results as <LOD. 
Of the 66 laboratories included in this study 21 (31%) used ICP-MS. At 1.48 μg/dL (a value 
close to the NHANES 2011–2012 75th percentile) or lower, approximately 50% of the 
laboratories reported actual values. Conversely, approximately 50% of the laboratories 
reported results as <LOD. The bias between CDC’s target value and the consensus mean 
was due to the high percent of laboratories reporting < LOD at the low target concentrations.
The distribution of reported LODs for the laboratories that have continuously participated in 
LAMP from 2011–2015 is shown in Table 5b.
Discussion
BLLs in U.S. children one to five years old have declined (see Figure) to a point that 
challenges the detection limit of many laboratories. Children with BLLs at or above the 90th 
or 97.5th percentile for NHANES 2011–2014 have characteristics similar to what has been 
reported in past studies of risk factors: less than three years old; male; non-Hispanic black; 
and living in low income households. This suggests that lead-based paint hazards continue to 
be a source of childhood lead exposure, but we did not have geographic details to determine 
residence location or housing age.15 We could not evaluate sources of exposure and 
contributions from other sources, including contaminated soil, dust, drinking water, and 
occasional sources such as cosmetics, remedies, hobbies, and occupational take-home. 
Although the NHANES 2011–2014 sample of one to five year old children was large, the 
97.5th percentile and higher was comprised of only 46 children. This contributes to the wide 
variability around 3.48 μg/dL, with a 95% confidence interval of 2.65 to 4.29 μg/dL. Despite 
this limitation, NHANES is the best and possibly only data source for U.S. population-based 
estimates.
BLLs of 5 μg/dL also present a clinical interpretation challenge. Although reported accuracy 
for most laboratories is ± 2 μg/dL (Parsons et al, 2001), the current CLIA acceptability 
criteria for accuracy in blood lead measurements of ±4 μg/dL (at values less than 40 μg/dL) 
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which means that the true value of a blood lead reported as 4 μg/dL can be between 0 and 8 
μg/dL. Therefore, when the child is retested, any result between 0 and 8 μg/dL includes the 
possibility that the true BLL is unchanged. It would be helpful for the clinician to explain to 
a parent or guardian the concept of variability in the measurement if, for example, a child’s 
BLL goes from 4 to 8 μg/dL in the absence of a new or increased exposure.
Since almost 23% of LAMP-participating laboratories reported LODs between 3 and 5 
μg/dL, it is likely that many laboratories will be unable to quantify blood lead at or near the 
97.5th percentile value (Table 5b). Forty percent of LAMP- participating laboratories were 
unable to quantify BLLs at around 1.5 μg/dL, implying that surveillance data collected from 
clinical laboratories for the general population could be at or below the LODs of many 
laboratories. So that LAMP participants can improve precision and accuracy of blood lead 
measurements below 5 μg/dL and to assist laboratories in testing new technology, CDC will 
include more challenge samples with target blood lead values between 1 and 5 μg/dL in 
future performance challenges.
Manufacturers of items such as blood collection materials and containers, cryovials, and 
reagents need increased awareness and to consider actions that avoid potential lead 
contamination during production of these items. Screening of blood collection devices is not 
feasible for most laboratories that provide blood lead measurements because they do not 
typically provide the blood collection materials. The EHL-DLS is finding it increasingly 
difficult to purchase manufactured lots that pass screening, and we anticipate that the 
percentage of device and reagent failures is likely to increase unless changes are made in 
manufacturing processes.
A tightening of the blood lead acceptability criteria in proficiency testing to ±2 μg/dL (≤20 
μg/dL) or ± 10% from ±4 μg/dL (≤40 μg/dL) or ± 10% will encourage laboratories to be 
aware of, and to proactively deal with contamination and measurement issues that often 
plague the analysis of blood lead at low levels. If laboratories are able to reduce 
contamination associated with their measurements, the limits of detection should improve. 
Currently, 33% of U.S. LAMP participating laboratories report a blood lead limit of 
detection ≥ 2 μg/dL (the 2013–2014 90th percentile for blood lead is 1.8 μg/dL). CDC will 
assist in reinforcing the need for blood lead laboratories to improvements contamination and 
measurement issues through the LAMP program. In 2017, LAMP reports will include telling 
participating laboratories how they would perform if a ±2 μg/dL or ±10% acceptance criteria 
were used.
Conclusion
The 97.5th percentile BLL based upon NHANES 2011–2014 results in children ages one to 
five years is 3.48 μg/dL, 30% lower than the current reference value of 5 μg/dL. Although 
the number of children in the sample that comprised the 97.5th percentile was small, they 
demonstrated previously identified risk factors for elevated BLLs: younger than three years 
old; male; non-Hispanic black; and living in low-income households. The continued 
decrease of BLLs in children presents challenges for clinicians, laboratories, and 
manufacturers of consumables and analytical instruments. To achieve precise and accurate 
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blood lead measurements with lower limits of detection, laboratories need to evaluate 
potential sources of external lead contamination, optimize their analytical methods for low 
concentration measurements, and participate in external proficiency testing programs, 
considering how they would perform if tighter acceptability criteria were used.
Manufacturers of devices used in blood lead sample collection could identify potential 
sources of lead contamination and take actions to reduce these sources. Clinicians should 
understand the factors affecting accurate measurements at very low blood lead 
concentrations to better interpret BLLs and assess whether small changes are real or indicate 
measurement variability.
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blood lead measurements (<5μg/dL).
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Figure. 
NHANES blood (μg/dL) lead geometric mean and 95th percentile by survey cycle. Note the 
steady decline in the blood lead levels in U.S. children since 1999.
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Table 3
Demographic distributions of the weighted-adjusted proportion (%) of U.S. children with blood lead levels (in 
μg/dL) at the 97.5th percentile or higher, vs. below the 97.5th percentile (NHANES 2011–2014)
<97.5th percentile1 ≥97.5th percentile1 P-value2
Age (years)
 1–2 38.0 (36.1─39.9) 52.6 (27.8─76.2) 0.0371
 3 - 4 43.0 (40.0─46.0) 37.0 (19.3─59.1)
 5 19.0 (16.9─21.3) 10.3 (5.3─19.3)
Gender
  Male 50.9 (48.3─53.5) 61.7 (37.8─81.1) 0.4299
  Female 49.1 (46.5─51.7) 38.3 (18.9─62.3)
Race/Ethnicity
 All Hispanic 27.4 (21.3─34.5) 13.7 (4.8─33.4) 0.0604
 Non-Hispanic Blacks 14.8 (11.2─19.2) 30.9 (10.4─63.3)
 Non-Hispanic Whites 52.8 (44.2─61.2) 52.8 (19.7─83.6)
 Non-Hispanic Asians 5.1 (3.9─6.6) 2.6 (0.4─16.6)
Annual Household Income
 < $20,000 20.6 (17.3─24.4) 40.8 (30.1─52.4) 0.0056
 ≥ $20,000 79.4 (75.6─82.7) 59.2 (47.6─69.9)
1
Results displayed are the proportion of children and (95% confidence interval).
2Chi square test
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Table 4
Results of multiple logistic regressions to examine associations between demographics and BLLs at the 90th 
percentile or higher in children ages 1–5 years, NHANES 2011–2014
Category ≥90 percentile P-value1
Age (years)
 1 -2 3.90 (1.69─8.99)* 0.0053
 3 - 4 2.44 (1.44─4.13)
5 1 (reference)
Gender
 Male 1.25 (0.82─1.90) 0.2898
 Female 1 (reference)
Race/Ethnicity
 All Hispanic 0.64 (0.32─1.28) 0.141
 Non-Hispanic Blacks 1.34 (0.64─2.81)
 Non-Hispanic Whites 1 (reference)
 Non-Hispanic Asians 1.19 (0.47─3.01)
Annual Household Income
 < $20,000 8.99 (5.05─16.01) <0.0001
 $20,000─$44,999 4.93 (2.71─8.98)
 ≥ $45,000 1 (reference)
1
odds ratio (95% confidence interval)
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Table 5b
Blood Lead Limits of Detection (LODs) for laboratories continuously participating in LAMP, 2011–2015
LOD Range (μg/dL) N of labs (percent)
<1 15 (22.7)
1 - <2 29 (43.9)
2 - <3 7 (10.6)
3 - 5 15 (22.7)
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